Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Coeptis Therapeutics Inc

Healthcare US COEP

NoneUSD
0.00(0%)

Last update at 2026-05-28T22:01:19.295194Z

Day Range

--
LowHigh

52 Week Range

6.2621.41
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap92.91M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.86229M
  • Revenue TTM1.36M
  • Revenue Per Share TTM0.32
  • Gross Profit TTM 1.18M
  • Diluted EPS TTM-2.81

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.27719M -10.87741M -21.26654M -37.57422M -13.44928M
Minority interest 0.36M 1.06M 0.00000M - -
Net income -11.91701M -10.87741M -21.26654M -40.96776M -14.42220M
Selling general administrative 1.15M 0.95M 3.95M 34.17M 14.12M
Selling and marketing expenses 0.10M 0.01M 0.01M 0.00833M 0.00292M
Gross profit -2.83254M -1.03863M -1.00124M 0.00000M 0.07M
Reconciled depreciation 1.22M 1.04M 1.00M 1.00M 0.45M
Ebit -13.04350M -10.48129M -21.15885M -34.19596M -14.04593M
Ebitda -11.82090M -9.44266M -20.15762M -32.96088M -12.81273M
Depreciation and amortization 1.22M 1.04M 1.00M 1.24M 1.23M
Non operating income net other - - - - -
Operating income -13.04350M -10.05449M -21.49113M -34.19596M -14.04593M
Other operating expenses 14.41M 10.05M 21.49M 34.20M 14.12M
Interest expense 0.64M 0.40M 0.11M 0.22M 0.19M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.12M 0.23M - - -
Net interest income -0.52588M -0.39612M -0.13620M -0.21841M -0.18713M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.36018M -1.06400M 3.39M 3.39M 0.97M
Total revenue 1.36M 0.00000M 0.00000M 0.00000M 0.07M
Total operating expenses 14.23M 9.02M 20.49M 34.20M 14.12M
Cost of revenue 4.20M 1.04M 1.00M 0.00000M 0.96M
Total other income expense net 0.77M -0.82292M 0.22M -3.37825M 0.60M
Discontinued operations - - - - -
Net income from continuing ops -12.27719M -10.87741M -20.18516M -37.57422M -13.44928M
Net income applicable to common shares - - - -37.57422M -13.44928M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19.84M 8.91M 8.07M 7.92M 6.77M
Intangible assets 0.36M 0.54M - - -
Earning assets - - - - -
Other current assets 0.99M 0.52M 0.24M 0.14M -
Total liab 2.09M 5.04M 3.76M 3.11M 4.41M
Total stockholder equity 17.25M 3.19M 4.31M 4.80M 2.35M
Deferred long term liab - - - - -
Other current liab 0.16M 2.01M 0.56M 0.18M 0.20M
Common stock 0.00057M 0.00021M 0.00353M 0.00196M 0.00355M
Capital stock 0.00057M 0.00021M 0.00353M 0.00196M 0.00355M
Retained earnings -109.95373M -98.23367M -87.35626M -65.73972M -27.55013M
Other liab - - - - -
Good will - - - - -
Other assets - - - 3.90M 0.00000M
Cash 5.67M 0.53M 1.47M 3.79M 2.18M
Cash and equivalents - - - - -
Total current liabilities 1.77M 4.51M 2.99M 1.82M 2.76M
Current deferred revenue 0.60M - - - 1.00M
Net debt -5.40543M 0.87M -0.24491M -2.08496M 1.90M
Short term debt 0.12M 1.23M 1.01M 1.54M 2.43M
Short long term debt 0.10M 1.19M 0.97M 1.50M 2.42M
Short long term debt total 0.27M 1.40M 1.22M 1.71M 4.08M
Other stockholder equity 127.20M 101.42M 91.67M 70.54M 29.90M
Property plant equipment - - - - 0.03M
Total current assets 7.35M 1.05M 5.25M 3.94M 2.18M
Long term investments 7.86M 5.69M - - -
Net tangible assets - - - 4.80M 2.35M
Short term investments 0.68M 0.00000M - - -
Net receivables 0.00735M 0.04M 3.54M 0.00808M 0.02M
Long term debt 0.15M 0.15M 0.15M 0.15M 1.65M
Inventory - - - - 0.00000M
Accounts payable 0.89M 1.27M 1.42M 0.10M 0.13M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.25M 1.56M 2.71M 3.90M 4.55M
Deferred long term asset charges - - - - -
Non current assets total 12.49M 7.86M 2.82M 3.97M 4.59M
Capital lease obligations 0.02M 0.06M 0.10M 0.06M 0.01M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00000M 0.00000M 0.00000M -1.75000M
Change to liabilities - - - -0.03507M -2.57815M
Total cashflows from investing activities - - - - -1.75000M
Net borrowings 0.77M 1.20M -0.57500M - -1.62241M
Total cash from financing activities 13.74M 5.71M 5.49M 5.49M 8.22M
Change to operating activities - - - -0.50719M -0.42334M
Net income -11.91701M -10.87741M -37.57422M -37.57422M -13.44928M
Change in cash 5.14M -0.93625M 1.61M 1.61M 1.98M
Begin period cash flow 0.53M 1.47M 2.18M 2.18M 0.20M
End period cash flow 5.67M 0.53M 3.79M 3.79M 2.18M
Total cash from operating activities -8.60304M -6.64928M -3.87581M -3.87581M -4.48944M
Issuance of capital stock 12.97M 4.01M 3.54M 3.27M 10.14M
Depreciation 1.22M 1.04M 1.00M 1.00M 0.45M
Other cashflows from investing activities - - - - -
Dividends paid - - - - 0.08M
Change to inventory - - - - -0.42202M
Change to account receivables -0.00735M -0.23474M -0.00808M -0.00808M 0.02M
Sale purchase of stock - - - 0.00000M -0.24716M
Other cashflows from financing activities - 4.41M 4.63M 4.63M 0.10M
Change to netincome - - - - 11.49M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 1.75M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.46005M -0.12526M -0.55034M -0.55034M -2.97970M
Stock based compensation 1.22M 1.10M 0.48M 0.00000M 1.90M
Other non cash items 2.34M 2.21M 33.25M 33.25M 4.26M
Free cash flow -8.60304M -6.64928M -3.87581M -3.87581M -6.23944M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
COEP
Coeptis Therapeutics Inc		 - -% - - - 68.17 6.85 63.70 -0.6407
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Coeptis Therapeutics Inc

105 Bradford Rd, Wexford, PA, United States, 15090

Key Executives

Name Title Year Born
Mr. David Mehalick Co-Founder, Chairman, CEO & Pres 1969
Ms. Christine Elise Sheehy Co-Founder, CFO & Sec. 1967
Mr. Daniel Alexander Yerace Co-Founder, VP of Operations & Director 1983
Mr. Gary R. Conte Sr. VP of Sales & Marketing NA
Mr. David Mehalick Co-Founder, Chairman of the Board, CEO & President 1969
Ms. Christine Elise Sheehy Co-Founder and VP of Compliance & Corporate Secretary 1968
Mr. Brian Cogley M.B.A. Chief Financial Officer 1987
Dr. Colleen Delaney M.D., M.Sc. CSO & Chief Medical Officer 1968
Ms. Christine Elise Sheehy Co-Founder, VP of Compliance & Corporate Secretary 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.